Remote: CMC Drug Substance Lead – Vaccine Process Transfer

Sabin Foundation Europe; Only (TN); On-site; USD 109,000 - 130,000; Full time

Job summary

Sabin Foundation Europe is seeking a Manager, CMC Drug Substance to provide technical leadership across vaccine drug substance development, including process development, characterization, technology transfer, and GMP manufacturing.

You will lead technology transfers, collaborate with CDMOs and internal teams to support scale-up, validation, regulatory, and commercial readiness, with a focus on expanding vaccine access and global health impact.

Qualifications

• Minimum 7+ years of experience in biopharmaceutical CMC, manufacturing, process development, and technology transfer.
• Hands-on experience with vaccine drug substance development and manufacturing.
• Experience leading technology transfers and working with CDMOs and external partners.
• Knowledge of adenovirus-vectored vaccines or viral vector platforms is preferred.
• Strong cross-functional collaboration and regulatory awareness.

Responsibilities

• Support vaccine development programs from late-stage to commercial supply.
• Lead tech transfer of a Phase 3 vaccine manufacturing process.
• Drive project execution with cross-functional teams and vendors.
• Ensure compliance with cGMP and regulatory expectations.
• Contribute to funding proposals and strategic planning.

Skills

Analytical skills

Cross-functional collaboration

Project leadership

Communication skills

Education

Bachelor’s degree in biochemistry, chemistry, biology, chemical engineering or related pharmaceutical science

Tools

cGMP experience

ICH guidelines knowledge

Regulatory submissions support

Job description

Sabin Foundation Europe is seeking a Manager, CMC Drug Substance to provide technical leadership across vaccine drug substance development, including process development, characterization, technology transfer, and GMP manufacturing.

You will lead technology transfers, collaborate with CDMOs and internal teams to support scale-up, validation, regulatory, and commercial readiness, with a focus on expanding vaccine access and global health impact.